ArticleDiscover oncology2026
Interplay between AIB1 genotypes and radiotherapy in a Swedish population-based breast cancer cohort.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHost factors, including genetic factors, are underutilized in breast cancer treatment selection. This study aimed to investigate AIB1 genotypes as pharmacogenetic markers for adjuvant breast cancer treatment. The prognostic impact of three functional polymorphisms associated with altered mRNA expression rs6094752 (low expression), rs2230782 (low expression) and rs2076546 (high expression) was studied in different treatment groups.
methodsAIB1 genotyping was performed using iPLEX™ on 576 breast cancer patients included 2002 − 2008 in Lund, Sweden, who were followed for up to 15 years. Clinicopathological data was obtained from questionnaires and patient charts. Diplotypes were constructed. Survival analyses were conducted with Kaplan-Meier curves, Log-Rank tests and multivariable Cox regression.
resultsThe most common AIB1 diplotypes were CGA_CGA (61.4%), CGA_CCA (16.4%), and CGA_CGG (12.0%). The remaining diplotypes were classified as ‘Rare’. Any breast cancer event was reported in 144 patients. There were significant interactions between radiotherapy and CGA_CGA (Pinteraction=0.033) or CGA_CCA (Pinteraction=0.017) on prognosis. In the 226 non-radiotherapy-treated patients, CGA_CGA carriers had the best prognosis, and CGA_CCA carriers the worst prognosis, with two-fold risk of breast cancer events in CGA_CCA compared with CGA_CGA carriers. In the 350 radiotherapy-treated patients, CGA_CGA was not associated with prognosis while CGA_CCA conferred 40% lower event risk. No other significant interactions between AIB1 diplotypes and chemotherapy, tamoxifen or aromatase inhibitors on prognosis were observed.
conclusionAIB1 genotypes conferred differential prognostic impact depending on adjuvant radiotherapy. If confirmed, AIB1 merits further evaluation as a putative pharmacogenetic marker to identify patients that benefit the most from radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.